Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monalizumab + Cetuximab in R/M SCCHN
NCT02643550Phase 2Completed
- Sponsor
- Innate Pharma
- Start
- Dec 2015
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of monalizumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Innate Pharma. Started Dec 2015; status: completed.
02
Drugs
monalizumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02643550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02643550.